ClinicalTrials.gg
CompletedNCT02516410Updated Jun 12, 2018Results posted

A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation

A Phase 3 interventional study of VX-661 plus ivacaftor combination and Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 43 sites in 7 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-06-12.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.

Enrollment
12th of 43
168 · median 100
Started
2015
with 4 others
Phase 3
25 of 43
none open now
Registered
8th of 43
by date
Lead sponsor
39 of 43
Vertex Pharmaceuticals Incorporated

Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 12th largest by enrollment, is one of 5 that started in 2015, is one of 25 in phase 3, and was the 8th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tezacaftor

tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tezacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

Study to evaluate the efficacy of VX-661 in combination with ivacaftor (IVA, VX-770) through Week 12 in participants with cystic fibrosis (CF) who are heterozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene and with a second CFTR mutation that is not likely to respond to VX-661 and/or IVA therapy (F508del/not responsive [NR]).

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of CF defined as a sweat chloride value greater than or equal to (>=)60 millimole per liter (mmol/L) by quantitative pilocarpine iontophoresis.
  • Heterozygous for the F508del-CFTR mutation and with a second CFTR mutation that is not likely to respond to VX-661 and/or ivacaftor therapy, genotype to be confirmed via assessment at the Screening Visit.
  • (FEV1) >=40 percent (%) and less than or equal to (\<=)90% of predicted normal for age, sex, and height at Screening Visit.

Exclusion criteria

Exclusion Criteria:

  • History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant.
  • An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 28 days before Day 1 (first dose of study drug).
  • History of solid organ or hematological transplantation.
  • Ongoing or prior participation in an drug study or use of commercially available CFTR modulator within 30 days of screening.
  • Pregnant or nursing females.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
168 participants (actual)

Study arms

  • Experimental
    VX-661/IVA

    VX-661 100 milligram (mg) plus IVA 150 mg fixed dose combination (FDC) tablet administered orally in the morning and IVA 150 mg film-coated tablet administered orally in the evening up to Week 12.

    Drug: VX-661 plus ivacaftor combination · Drug: Ivacaftor

  • Placebo comparator
    Placebo

    Placebo matched to VX-661 plus IVA FDC tablet administered orally in the morning and placebo matched to IVA film-coated tablet administered orally in the evening up to Week 12.

    Drug: Placebo (matched to VX-661 plus ivacaftor combination) · Drug: Placebo (matched to ivacaftor)

Interventions

  • DrugVX-661 plus ivacaftor combination

    Drug pages: Tezacaftor · Ivacaftor

  • Also known as: IVA, VX-770

  • DrugPlacebo (matched to VX-661 plus ivacaftor combination)
  • DrugPlacebo (matched to ivacaftor)
06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 12

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years.

    Time frame: Baseline, Through Week 12

Secondary outcomes

  1. Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 12

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: Baseline, Through Week 12

  2. Number of Pulmonary Exacerbation Events

    Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. The number of events were reported.

    Time frame: Baseline through Week 12

  3. Number of Pulmonary Exacerbation Events Per Year

    Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Total number of days on study is equal to the Week 12 date or the last dose date (whichever occurs last) minus first dose date plus 1. The total number of years (48 weeks) on study is equal to the total number of days on study divided by 336. Pulmonary exacerbation events per year (48 weeks) are reported.

    Time frame: Baseline through Week 12

  4. Absolute Change From Baseline in Body Mass Index (BMI) at Week 12

    BMI was defined as weight in kilogram (kg) divided by height\*height in square meter (m\^2).

    Time frame: Baseline, Week 12

  5. Relative Change From Baseline in Percent Predicted FEV1 Through Week 12

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years.

    Time frame: Baseline, Through Week 12

  6. Absolute Change From Baseline in Sweat Chloride Through Week 12

    Sweat samples were collected using an approved collection device.

    Time frame: Baseline, Through Week 12

  7. Number of Participants With at Least One Pulmonary Exacerbation Through Week 12

    Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Time-to-first pulmonary exacerbation was planned to be estimated using Kaplan-Meier (KM) estimates. However, due to less than 50% of events, time-to-first event data was not estimated. Instead, number of participants with at least one pulmonary exacerbation event were collected and are reported.

    Time frame: Baseline through Week 12

  8. Absolute Change From Baseline in BMI Z-score at Week 12 (in Participants Less Than [<] 20 Years Old at the Time of Screening)

    Z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is, with range from infinity to +infinity; where 0: same mean, \>0: a greater mean, and \<0: a lesser mean than the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age Z-score (BMI z-score). BMI-for-age z-score was calculated by using centers for disease control and prevention (CDC) growth charts for the paediatric population.

    Time frame: Baseline, Week 12

  9. Absolute Change From Baseline in Body Weight at Week 12

    Time frame: Baseline, Week 12

  10. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AE that increased in severity or newly developed at or after initial dosing of study drug to Week 16 was considered treatment-emergent.

    Time frame: Baseline up to Week 16

  11. Trough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolite (M1 VX-661), Ivacaftor (IVA) and IVA Metabolite (M1-IVA)

    This outcome was not planned to be assessed in Placebo arm.

    Time frame: Pre-morning dose on Week 2, Week 4, Week 8 and Week 12

07

Results

Posted Jun 12, 2018

Participant flow

The study was conducted across 38 sites in 7 countries.

Participant flow — Overall Study
MilestonePlaceboVX-661/IVA
Started8583
Completed8581
Not completed02
Withdrew: Adverse event01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryAbsolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 12

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years.

Time frame:
Baseline, Through Week 12
Reported as:
Least squares mean · Percentage of predicted FEV1
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 12
Percentage of predicted FEV1PlaceboVX-661/IVA
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 12-0.1 ± 0.61 ± 0.6
Statistical analysis
  • Placebo vs VX-661/IVA · Mixed-effect repeated measure (MMRM) · p = = 0.1176 · Least squares (ls) mean difference: 1.2 · 95% CI -0.3 to 2.6
SecondaryAbsolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 12

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
Baseline, Through Week 12
Reported as:
Least squares mean · Units on a scale
Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 12
Units on a scalePlaceboVX-661/IVA
Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 123.8 (1.1 to 6.4)5.9 (3.2 to 8.5)
SecondaryNumber of Pulmonary Exacerbation Events

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. The number of events were reported.

Time frame:
Baseline through Week 12
Reported as:
Number · Pulmonary exacerbation events
Number of Pulmonary Exacerbation Events
Pulmonary exacerbation eventsPlaceboVX-661/IVA
Number of Pulmonary Exacerbation Events2322
SecondaryNumber of Pulmonary Exacerbation Events Per Year

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Total number of days on study is equal to the Week 12 date or the last dose date (whichever occurs last) minus first dose date plus 1. The total number of years (48 weeks) on study is equal to the total number of days on study divided by 336. Pulmonary exacerbation events per year (48 weeks) are reported.

Time frame:
Baseline through Week 12
Reported as:
Number · Pulmonary exacerbation events per year
Number of Pulmonary Exacerbation Events Per Year
Pulmonary exacerbation events per yearPlaceboVX-661/IVA
Number of Pulmonary Exacerbation Events Per Year0.980.97
SecondaryAbsolute Change From Baseline in Body Mass Index (BMI) at Week 12

BMI was defined as weight in kilogram (kg) divided by height\*height in square meter (m\^2).

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Kg/m^2
Absolute Change From Baseline in Body Mass Index (BMI) at Week 12
Kg/m^2PlaceboVX-661/IVA
Absolute Change From Baseline in Body Mass Index (BMI) at Week 120.22 (0.07 to 0.36)0.14 (-0.01 to 0.28)
SecondaryRelative Change From Baseline in Percent Predicted FEV1 Through Week 12

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years.

Time frame:
Baseline, Through Week 12
Reported as:
Least squares mean · Percent Change
Relative Change From Baseline in Percent Predicted FEV1 Through Week 12
Percent ChangePlaceboVX-661/IVA
Relative Change From Baseline in Percent Predicted FEV1 Through Week 120.1 (-2.1 to 2.3)2.1 (-0.1 to 4.3)
SecondaryAbsolute Change From Baseline in Sweat Chloride Through Week 12

Sweat samples were collected using an approved collection device.

Time frame:
Baseline, Through Week 12
Reported as:
Least squares mean · Millimole per liter (mmol/L)
Absolute Change From Baseline in Sweat Chloride Through Week 12
Millimole per liter (mmol/L)PlaceboVX-661/IVA
Absolute Change From Baseline in Sweat Chloride Through Week 12-1.2 (-3.1 to 0.7)-4.7 (-6.6 to -2.8)
SecondaryNumber of Participants With at Least One Pulmonary Exacerbation Through Week 12

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Time-to-first pulmonary exacerbation was planned to be estimated using Kaplan-Meier (KM) estimates. However, due to less than 50% of events, time-to-first event data was not estimated. Instead, number of participants with at least one pulmonary exacerbation event were collected and are reported.

Time frame:
Baseline through Week 12
Reported as:
Count of participants · Participants
Number of Participants With at Least One Pulmonary Exacerbation Through Week 12
ParticipantsPlaceboVX-661/IVA
Number of Participants With at Least One Pulmonary Exacerbation Through Week 122119
SecondaryAbsolute Change From Baseline in BMI Z-score at Week 12 (in Participants Less Than [<] 20 Years Old at the Time of Screening)

Z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is, with range from infinity to +infinity; where 0: same mean, \>0: a greater mean, and \<0: a lesser mean than the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age Z-score (BMI z-score). BMI-for-age z-score was calculated by using centers for disease control and prevention (CDC) growth charts for the paediatric population.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Z-score
Absolute Change From Baseline in BMI Z-score at Week 12 (in Participants Less Than [<] 20 Years Old at the Time of Screening)
Z-scorePlaceboVX-661/IVA
Absolute Change From Baseline in BMI Z-score at Week 12 (in Participants Less Than [<] 20 Years Old at the Time of Screening)0.07 (-0.05 to 0.19)0.02 (-0.09 to 0.13)
SecondaryAbsolute Change From Baseline in Body Weight at Week 12
Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Kilograms (kg)
Absolute Change From Baseline in Body Weight at Week 12
Kilograms (kg)PlaceboVX-661/IVA
Absolute Change From Baseline in Body Weight at Week 120.7 (0.3 to 1.1)0.6 (0.2 to 1.0)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AE that increased in severity or newly developed at or after initial dosing of study drug to Week 16 was considered treatment-emergent.

Time frame:
Baseline up to Week 16
Reported as:
Number · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPlaceboVX-661/IVA
Participants with any AEs6864
Participants with any SAEs1411
SecondaryTrough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolite (M1 VX-661), Ivacaftor (IVA) and IVA Metabolite (M1-IVA)

This outcome was not planned to be assessed in Placebo arm.

Time frame:
Pre-morning dose on Week 2, Week 4, Week 8 and Week 12
Reported as:
Mean · nanogram per milliliter (ng/mL)
Trough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolite (M1 VX-661), Ivacaftor (IVA) and IVA Metabolite (M1-IVA)
nanogram per milliliter (ng/mL)VX-661/IVA
Week 2: VX-6611880 ± 1230
Week 2: M1 VX-6614600 ± 1430
Week 2: IVA831 ± 607
Week 2: M1-IVA1580 ± 879
Week 4: VX-6611780 ± 1010
Week 4: M1 VX-6614420 ± 1340
Week 4: IVA770 ± 596
Week 4: M1-IVA1500 ± 898
Week 8: VX-6611920 ± 2170
Week 8: M1 VX-6614330 ± 1980
Week 8: IVA747 ± 745
Week 8: M1-IVA1370 ± 1070
Week 12: VX-6611700 ± 1220
Week 12: M1 VX-6614290 ± 1730
Week 12: IVA776 ± 690
Week 12: M1-IVA1620 ± 1160

Adverse events

Collected over Baseline up to Week 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/85 (0%)14/85 (16.5%)63/85 (74.1%)
VX-661/IVA0/83 (0%)11/83 (13.3%)62/83 (74.7%)
Most frequent serious events
Most frequent serious events
EventPlaceboVX-661/IVA
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations12/856/83
Distal intestinal obstruction syndromeGastrointestinal disorders0/853/83
HaemoptysisRespiratory, thoracic and mediastinal disorders1/852/83
Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/851/83
Lower respiratory tract infection bacterialInfections and infestations0/851/83
Pulmonary function test decreasedInvestigations1/850/83
Productive coughRespiratory, thoracic and mediastinal disorders1/850/83
InfluenzaInfections and infestations1/850/83
SinusitisInfections and infestations1/850/83
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlaceboVX-661/IVA
CoughRespiratory, thoracic and mediastinal disorders27/8519/83
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations15/8517/83
Sputum increasedRespiratory, thoracic and mediastinal disorders12/857/83
FatigueGeneral disorders4/8510/83
HaemoptysisRespiratory, thoracic and mediastinal disorders6/858/83
Nasal congestionRespiratory, thoracic and mediastinal disorders8/857/83
DyspnoeaRespiratory, thoracic and mediastinal disorders7/855/83
HeadacheNervous system disorders7/855/83
NauseaGastrointestinal disorders6/856/83
Oropharyngeal painRespiratory, thoracic and mediastinal disorders6/855/83

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboVX-661/IVATotal
Mean26 ± 8.826.2 ± 9.626.1 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVX-661/IVATotal
Female423981
Male434487
08

Study locations

43 sites
  • Birmingham, Alabama, United States
  • La Jolla, California, United States
  • Los Angeles, California, United States
  • Denver, Colorado, United States
  • Miami, Florida, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Indianapolis, Indiana, United States
  • New Orleans, Louisiana, United States
  • Ann Arbor, Michigan, United States
  • Detroit, Michigan, United States
  • Minneapolis, Minnesota, United States
  • Kansas City, Missouri, United States
  • Omaha, Nebraska, United States
  • New York, New York, United States
  • Cincinnati, Ohio, United States
  • Memphis, Tennessee, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • Richmond, Virginia, United States
  • Seattle, Washington, United States
  • Spokane, Washington, United States
  • Brisban, Queensland, Australia
  • Chermside, Australia
  • Herston, Australia
  • Innsbruck, Australia
  • Westmead, Australia
  • Graz, Austria
  • Innsbruck, Austria
  • Salzburg, Austria
  • Vancouver, British Columbia, Canada
  • Montreal, Canada
  • Bron Cedex, France
  • Montpellier Cedex 5, France
  • Paris Cedex 14, France
  • Paris Cedex 19, France
  • Paris, France
  • Haifa, Israel
  • Hashomer, Israel
  • Jerusalem, Israel
  • Petah Tikva, Israel
  • Barcelona, Spain
  • Valencia, Spain
09

References and documents

Publications

  • Munck A, Kerem E, Ellemunter H, Campbell D, Wang LT, Ahluwalia N, Owen CA, Wainwright C. Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations. J Cyst Fibros. 2020 Nov;19(6):962-968. doi: 10.1016/j.jcf.2020.04.015. Epub 2020 Jun 13. PubMed 32546431 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2015, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2018, 2 years after primary completion. A results delay was requested in Jun 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2015
First posted
Aug 5, 2015
Start
Aug 2015
Primary completionActual
Jun 7, 2016
CompletionActual
Jun 7, 2016
Results delay requested
Jun 8, 2017
Results first posted
Jun 12, 2018
Last update
Jun 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02516410
Responsible party
Sponsor
First posted
Aug 5, 2015
Start date
Aug 2015
Primary completion
Jun 7, 2016
Completion
Jun 7, 2016
Results posted
Jun 12, 2018
Last update
Jun 12, 2018

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tezacaftor · Ivacaftor

Start the discussion